C677T gene polymorphism of MTHFR and metabolic syndrome: response to dietary intervention by L. Di Renzo et al.
Di Renzo et al. Journal of Translational Medicine 2014, 12:329
http://www.translational-medicine.com/content/12/1/329RESEARCH Open AccessC677T gene polymorphism of MTHFR and
metabolic syndrome: response to dietary
intervention
Laura Di Renzo1*, Luigi Tonino Marsella2, Francesca Sarlo3, Laura Soldati4, Santo Gratteri5, Ludovico Abenavoli6
and Antonino De Lorenzo1,7,8Abstract
Background: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms were found associated with body
mass index (BMI)-defined obesity and lean mass.
The aim of our study was to examine the role of the C677T MTHFR gene polymorphism in the response to diet in
the management of metabolic syndrome. We investigated the body composition and metabolic factor changes
after an hysocaloric balanced diet (HBD), in Italian obese women affected by metabolic syndrome (MS).
Methods: Forty four obese women affected by MS were eligible for the study. A HBD for 12 weeks was assigned.
Study participation included a complete screening for dietary habits, anthropometry, body composition, blood
biochemical markers and C677T MTHFR polymorphism genotyping. The study has been registrated by ClinicalTrials.
gov Id: NCT01890070.
Results: The highest number of responders to HBD nutritional intervention were T(−) carriers (p≤ 0.05). In the 81%
of the total population a loss of Total Body Lean was observed. A significative loss (p≤ 0.05) of Total Body Lean was
observed in the 47% of T(−) carriers and in the 53% of T(+) carriers. Diastolic and systolic blood pressure, and waist
circumference were reduced (p≤ 0.05). The prevalence of MS parameters decreased by 84% for systolic and
diastolic blood pressure; 79,5% for HDL cholesterol, 82% for fasting glucose and 77% for triglycerides.
Conclusions: MTHFR genetic variations analysis would be an innovative tool for the nutritional assessment. Our
data provide the basis for personalized dietary recommendations based on the individual’s genetic makeup and
nutritional status.
Trial registration: The study has been registrated by ClinicalTrials.gov Id: NCT01890070.
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According to the definition of World Health Organization
WHO, obesity is a condition char-acterised by a large in-
crease of body fat [1]. Body weight and its component are
related to energy expenditure and metabolic risk. Patho-
genic events related to changes in fat mass are basis of the
obesity: fat amount and its distribution is a critical value. In
particular, high fat mass has been associated to increased
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unless otherwise stated.cardiovascular disease (CVD) [2]. Therefore, high-risk man-
agement strategies remain important as long as the disease
is widely prevalent, and intervention to target population
level behavior is critically needed. To this aim, the cluster-
ing of certain metabolic factors (e.g., abdominal obesity,
dyslipidemia and elevated blood pressure), that define the
metabolic syndrome (MS), has been documented to identify
patients at increased risk for type 2 diabetes, as well as
CVD and overall mortality [3,4]. The MS is a growing
health problem worldwide with an estimated prevalence in
developed countries of 25–35% in adults, in parallel with
the increasing prevalence of obesity and diabetes. [5]. A
similar increase has also involved the Mediterraneanal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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obesity, and sedentary way of life.
Beyond metabolic factors, the genetic background may
affect the risk of cardiometabolic diseases, expecially in
women in the post-menopausal period. Indeed, there
are data suggesting the existence of significant gene-
environment interaction effects that make some individ-
uals more susceptible to body weight gain or loss than
others because of genetic differences, when exposed to
an obesogenic environment. Moreover, body compos-
ition changes could be partially explained by genetic
factors or by the interaction between genes and environ-
ment [7,8].
Personalized risk prediction and strategic health-care
planning will facilitate a new form of care, which is
called ‘prospective health care’ [9]. However, in order to
provide an individual and personalized health plan, new
tools and predictive biomarkers are needed.
Methylenetetrahydrofolate reductase (MTHFR), by
catalyzing the conversion of 5, 10 methylenetetrahydro-
folate to 5-methyltetrahydrofolate, is a pivotal enzyme in
folate metabolism that regulates the proportional usage
of one-carbon units between methylation reactions and
nucleic acid synthesis. The C677T MTHFR gene poly-
morphism results in a reduced specific MTHFR activity
(~34% residual activity in T677T, ~71% residual activity
in C677T relative to C677C).
The MTHFR gene polymorphisms were also found to
be associated with body mass index (BMI)-defined obes-
ity and lean mass, sustaining a linkage of body mass
index (BMI) and lean mass to chromosome 1p36, where
the MTHFR gene is located [10,11].
However, weight loss and the body mass index (BMI)
lack sensitivity to detect total body lean mass (TBLean)
loss. Moreover, BMI alone may not be enough accurate
for assessing the extent of excessive fat accumulation
and thus the obesity related disease risk, because it does
not directly measure the total body fat mass (TBFat).
Body composition evaluation is a valuable technique to
assess nutritional status, because it gives a precise evalu-
ation of nutritional status through the assessment of
TBFat, TBLean, and bone mass, allowing evaluation of
the disease prognosis and outcome [12], providing more
reliable and precise measure for obesity [13,14]. Dual en-
ergy X-ray absorptiometry (DXA) can measure body
composition, and DXA-derived TBLean measures can
reflect both muscle mass and muscle strength [15], pro-
viding a reliable measure for assessment of sarcopenia
[16], and obesity [17].
Furthermore, we have shown a significant relationship
between the Normal Weight Obese phenotype, a status
of TBFat accumulation accompanied by TBLean defi-
ciency, and possession of wild type and heterozygous ge-
notypes of C677T MTHFR enzyme polymorphism [18].These results jointly imply that MTHFR may play a role
in variation of TBLean.
Due to recent lines of evidence supporting the func-
tional and genetic relevance of C677T MTHFR gene poly-
morphism, this study was designed to determine the role
of this polymorphism in the response to hysocaloric bal-
anced diet (HBD), in terms of weight lost, body compos-
ition, blood pressure, and gluco-lipid profile, in Italian
women with MS.
Methods
Study design and subjects
We used intervention study design where each subject
acts as their own control group with repeated measures,
at baseline and after 12 weeks nutritional intervention
period.
A total of 50 participants were consecutively recruted
by Clinical Nutrition and Nutrigenomic Division of Uni-
versity of Rome Tor Vergata during three months from
May 2013. Participation in the study included a complete
medical history to gather informations about health status,
current medications history, including supplements of vi-
tamins and minerals, social habits, like alcohol drinking
and smoking, food habits, physical activity and family his-
tory for chronic diseases, a complete screening of anthro-
pometry and body composition, and a genotyping for the
C677T MTHFR polymorphism. Subjects having serious
chronic diseases/conditions that may have potential influ-
ence on endocrine and metabolism were excluded
The study group consisted of 44 obese women affected
by MS. The subjects were classified as obese, according
to WHO criteria [19], and percentage of total body fat
(PBF) cutoff points [13].
A multidisciplinary team of dieticians and nutritionists
met with each patient, and provided an educational ses-
sion for nutrition and meal-planning guidance.
A balanced hysocaloric diet for 12 weeks was assigned
to all eligible subjects. None of the subjects was receiv-
ing drug treatments at the time of the assessment.
A statement of informed consent was signed by all partic-
ipants in accordance with principles of the Declaration of
Helsinki. Nutritional status assessment was conducted at
the Obesity Centre of Nicotera Hospital (VV, Italy). Genetic
analysis was performed at the Clinical Nutrition and Nutri-
genomic Section, Department of Biomedicine and Preven-
tion of University of Rome Tor Vergata.
Physical Activity (PA) assessment
Leisure time and PA habits were monitored using a vali-
dated questionnaire [20]. No change of total energy expend-
iture (kcal/day) was required during the experimental time.
Participants were asked to maintain their usual exercise
habits during 3 months of follow-up after the beginning of
the nutritional intervention.
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The macronutrient’s composition of the HBD, [21] was as
follows: 55% of kcal/day from carbohydrates; 15% of kcal/
day from proteins; 30% of kcal/day from lipids (saturated
fat ≤10%; poliunsaturated fatty acids (PUFA) 6–10%: 5–6%
of n-6 PUFA and 1–2% of n-3 PUFA; monounsaturated
fatty acids (MUFA), about 15%; trans fatty acids ≤1%).
The HBD was performed as hypocaloric, respect to
the dietary habitus, taking into account the resting meta-
bolic rate (RMR) of each subjects, calculated using De
Lorenzo et al. prediction equation for the Italian popula-
tion [22], and level of PA [20].Anthropometric measurements
After a 12-h overnight fast, all subjects underwent an-
thropometric evaluation. Anthropometric parameters of
all the participants were measured according to stand-
ard methods (body weight, height, waist and hip cir-
cumferences) [23]. Subjects were instructed to take off
their clothes and shoes before performing all the mea-
surements. Body weight (Kg) was measured to the near-
est 0.1 Kg, using a balance scale (Invernizzi, Rome,
Italy). Height (cm) was measured using a stadiometry to
the nearest 0.1 cm (Invernizzi, Rome, Italy). The waist
(WC) and hip (HC) circumferences were measured with
a flexible steel metric tape to the nearest 0.5 cm. WC
was measured at the horizontal plane that corresponds
with the narrowest point between the crest iliac and the
bottom rib. HC was measured at the largest point when
observed on a horizontal plane. BMI was calculated
using the formula: BMI = body weight (Kg)/height (m)2.Dual-energy X-ray absorptiometry (DXA)
Body composition analysis was assessed by DXA (i-DXA,
GE Medical Systems, Milwaukee, WI, USA), according to
the previously described procedure, for evaluating soft tis-
sues, i.e. TBFat and TBLean [24,25]. The subjects were
instructed not to exercise within 24 h from the test. The
subjects were given complete instructions on the testing
procedure. They wore a standard cotton t-shirt, shorts
and socks. They laid supin on the DXA, without moving
while the DXA scan recorded their results. The average
measurement time was 20 min. Radiation exposure was
equivalent to 0.01 mSv. The coefficient of variation (CV%
=100 × s.d./mean) intra- and intersubjects ranged from 1
to 5%. The coefficient of variation for bone mass measure-
ments is ≤1%; coefficient on this instrument for five sub-
jects scanned six times over a 9-month period were 2.2%
for TBFat and 1.1% for TBLean.
The resting metabolic rate (RMR) of each subjects,
was calculated using De Lorenzo et al. prediction equa-
tion for the Italian population, and level of PA [22].Clinical and metabolic variables
The blood pressure was taken using a manual mercury
sphygmomanometer from the right upper arm after the
subject was seated quietly for at least 5 min (average of
three measurements).
Blood samples (10 mL) were collected into sterile tubes
containing EDTA (Vacutainer®). All materials were imme-
diately placed on ice and plasma was separated by centri-
fugation at 1600 × g for 10 min at 4°C.
Serum laboratory tests included fasting glucose, HDL-
cholesterol and Triglycerides at baseline and after 12 weeks
of HBD. Fasting glucose concentrations were measured
using the glucose oxidase method with an automated glu-
cose analyzer (COBAS INTEGRA 400, Roche Diagnostics,
Indianapolis, IN, USA), serum lipid profile components
were determined by standard enzymatic colorimetric tech-
niques (Roche143 Modular P800, Roche Diagnostics, In-
dianapolis, IN, USA).
Analyses were carried out by the accredited Clinical
Chemical Laboratories of the Hospital of Nicotera, Italy.
The Diagnosis of MS was based on the International
Diabetes Federation (IDF) guidelines [26]. Diagnosis re-
quired central obesity, defined as waist circumference
≥80 cm for European women, plus any two of the fol-
lowing four factors: TG level ≥150 mg/dL or specific
treatment for this lipid abnormality; HDL cholesterol
≤40 mg/dL in males and ≤50 mg/dL in females or spe-
cific treatment for this lipid abnormality; systolic blood
pressure (SBP) ≥130 mm Hg or diastolic blood pressure
(DBP) ≥85 mm Hg or anti-hypertensive treatment; fast-
ing plasma glucose ≥100 mg/dL or previously diagnosed
type 2 diabetes.
MTHFR genotype analysis
DNA was isolated from peripheral leukocytes by using the
Gentra DNA isolation kit (Gentra Systems Inc, Minneapolis,
MN, USA). According to a previously described procedure,
genotyping for the MTHFR point polymorphism C677T
was performed by polymerase chain reaction amplification
with the primers 5′TGAAGGAGAAGGTGTCTGCGGG
A3′ (sense) and 5′AGGACGGTGCGGTGAGAGTG3′
(antisense). Thirty cycles (95°C for 45 s, 64°C for 30 s, and
72°C for 30 s) were used to amplify the 198-base pair (bp)
product. Because the C-to-T transition at nucleotide 677
produces a HinfI digestion site, the amplified product de-
rived from the mutant gene was cleaved into 175-bp and
23-bp fragments by HinfI, which leaves the wild-type gene
unaffected. After electrophoresis through a 6% polyacryl-
amide gel, the digestion products were visualized by staining
with ethidium bromide.
Statistical analysis
Data are presented as group means (or median) ± stand-
ard deviation (SD), percentage, or ≤DELTA% > (Δ%). Δ%
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respect to baseline. For the calculation we used the fol-
lowing formula:
Δ%= [(value at week 12) – (value at baseline)/(value at
baseline)] ∗100.
Sample size was selected to provide a statistical power
of 95% to detect a reduction of 50% for the MS, with
alpha =0.05.
Data were analyzed to check assumptions about the
distribution of the measured variables. Three genotype
groups were first considered to check differences in con-
sidered variables between groups. Because a dominant
or recessive effect existed, analysis was repeated compar-
ing carriers T(+) vs non-carriers T(−) groups. An inde-
pendent t test were performed to evaluate differences
before and after HBD nutritional intervention. The
probability values are 2-sided; a probability value ≤0.05
was considered to indicate statistical significance. Statis-
tical analysis was performed using a computer software
package (SPSS for Windows, version 13.0; SPSS Inc.,
Chicago, IL, USA).
Results
Dietary and physical assessment
Of all recruited women, 44 of them (88%, age: 50.20 ±
10.12 years) completed the study, due to the lost of
follow-up of 6 subjects, and their results were eligible
for data analysis. According to WHO criteria of obesity,
all subjects were obese with a BMI between 56.23 kg/m2
and 33.37 kg/m2 at the starting point, before the nutri-
tional intervention.
Dietary assessment is reported in Table 1. A compari-
son of macronutrients and micronutrients between base-
line and HBD nutritional intervention is highlighted.
The level of PA was classified into three categories
(sedentary, moderate and vigorous) based on the time
spent on life activity or programmed physical exercise.
According to PA questionnaire, at baseline, no subjectsTable 1 Dietary assessment at baseline and after HBD
nutritional intervention1
Baseline HBD nutritional intervention
Nutrients
Energy (Kcal/day) 2950 ± 390 2410 ± 215
Carbohydrates (% en) 48 ± 2 53 ± 1
Lipids (% en) 35 ± 1 26 ± 1
Proteins (% en) 13 ± 1 17 ± 1
Fiber (g/die) 18 ± 4 33 ± 2
Folate (μg/die) 275 ± 50 466 ± 20
Vitamin B12 (μg/die) 3 ± 1 5 ± 1
Vitamin B6 (μg/die) 2 ± 1 2 ± 1
1Values expressed as mean ± SD.spent time for vigorous PA, the most spent 1–2 times/
week for moderate PA, with a sedentary behavior ran-
ging from 10 to 16 h/day. Nobody changed the level of
PA during the HBD period.
Genotyping assessment
According conventional formula of the Hardy-Weinberg
rule, the T allele frequency was 2.13%, and the CC, CT,
and TT genotype frequencies were 62%, 33.5%, and 4.5%,
respectively. The T allele frequency in our sample was
similar to that in other white populations. The study
population was divided in 2 subgroups, i.e. T(+) carriers
and T(−) non-carriers of the C677T MTHFR gene
polymorphism.
The T(+) and T(−) frequency was 54.5% (n =24), and
45.5% (n =20), respectively.
MS components
MS componenets at baseline and after HBD, for total
population and according to MTHFR genotypes, are
given in Table 2.
In the total population, the WC, SBP, DBP showed the
most changes (p ≤ 0.05). After HBD nutritional interven-
tion, a significant decreased level (p ≤ 0.05) of fasting
blood glucose was observed in T(−) carries levels. More-
over, in T(+) and T(−) carriers significant decreased level
of triglycerides was highlighted (p ≤ 0.05).
Moreover, 57% of T(+) carrier did not ameliorated
SBP and DBP, 56% T(+) carrier did not ameliorated
HDL-C, 75% T(+) carrier did not ameliorated fasting
glucose, and 60% T(+) carrier did not ameliorated tri-
glycerides values.
Anthropometric and body composition parameters
Table 3 shows the distribution of obese subject accord-
ing to obesity degree at baseline and after HBD.
Anthropometric parameters, and body composition
characteristics by DXA, at baseline for total population
and according to MTHFR genotypes, are given in Table 4.
After 12 weeks HBD nutritional intervention, significant
decreases in body weight (p ≤ 0.05), BMI (p ≤ 0.001), waist
and abdomen circumpherences (p ≤ 0.05), TBFat (p ≤ 0.05)
and TBLean were observed in the total population.
Dietary treatment success was achieved by all subjects.
Of total subjects, all decreased in terms of weight and
TBFat: nobody increased weight.
At baseline, T(+) carriers had higher body weight, waist
circumpherence, TBFat, TBLean, PBFat and BMD total
body respect to T(−) carriers.
Table 5 shows the comparison of body composition
relative changes (Δ%) according to genotype.
Significant Δ% TBFat (p ≤ 0.05) were observed between
T(−) carriers and T(+) carrier. Moreover, significant Δ%
TBLean (p ≤ 0.05) were observed between total population
Table 2 Comparison of clinical parameters of metabolic syndrome at baseline and after HBD nutritional intervention1
Parameters Baseline Week 12
Total (n = 44) T (−) (n = 20) T (+) (n = 24) Total (n = 44) T (−) (n = 20) T (+) (n = 24)
Waist (cm) 111.83 ± 11.65 106.06 ± 10.63 116.17 ± 10.80d 103.50 ± 13.07a 97.50 ± 12.74b 108.00 ± 11.87c
SBP (mmHg) 131.67 ± 12.96 135.56 ± 13.33 128.75 ± 12.43 121.05 ± 10.12a 119.67 ± 12.54b 122.08 ± 10.33
DBP (mmHg) 84.33 ± 9.45 84.44 ± 11.30 84.25 ± 8.32 75.48 ± 6.10a 75.56 ± 7.26 75.42 ± 5.42c
Fasting Glucose (mg/dl) 109.68 ± 22.33 115.33 ± 25.72 104.60 ± 18.66d 97.24 ± 7.83 93.57. ± 7.74b 99.80 ± 7.16e
HDL-C (mg/dl) 44.88 ± 11.67 46.59 ± 11.79 43.55 ± 9.58 47.40 ± 15.50 49.15 ± 7.30 46.22 ± 10.78
Triglycerides (mg/dl) 171.11 ± 71.49 164.33 ± 64.31 177.90 ± 79.50d 166.47 ± 64.94 142.62 ± 59.04b 173.57 ± 63.28
1All values are mean ± SD. SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL-C: HDL cholesterol.
aReflects the significance of the differences between total population at baseline vs total population at week 12 determined with an independent t test (p ≤ 0.05).
bReflects the significance of the differences between T(−) carrier at baseline vs T(−) carrier at week 12 determined with an independent t test (p ≤ 0.05).
cReflects the significance of the differences between T(+) carrier at baseline vs T(+) carrier at week 12 determined with an independent t test (p ≤ 0.05).
dReflects the significance of the differences between T(−) carrier at baseline vs T(+) carrier at baseline determined with an independent t test (p ≤ 0.05).
eReflects the significance of the differences between T(−) carrier at week 12 vs T(+) carrier at week 12 determined with an independent t test (p ≤ 0.05).
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Discussion
Globally, the prevalence of metabolic syndrome is in-
creasing, largely because of obesity resulting from poor
diets and sedentary lifestyles. Moreover, impaired glu-
cose tolerance and diabetes mellitus may be found in
nearly 20% of women age 55–65 years, and high blood
glucose is globally the third leading cause of premature
mortality [27]. Furthermore, studies showed that individ-
uals with sarcopenic obesity had the highest morbidity
and mortality [28], and that lean body mass exerts a pro-
tective effect against all cause mortality [29]. A dietary
approach might significantly help prevent and treat the
metabolic imbalance, and a correct life style is necessary
to preserve health status and wellbeing. Lifestyle changes
(LC) interventions, such as dietary changes and physical
activity, have a main role in treatment of the MS [30,31].
However, it has long been suspected that “one size
does not fit all” in terms of determining the optimal diet
for an individual, and this has been demonstrated over
the years in studies on gene-diet interactions and with
the emergence of nutrigenetics [32].
It’s an emerging area that genetic variants could be
considered in obesity and disease management for their
additive effects [33-35].
Strategies to improve weight maintenance are nowday
focused on considering together the genetic makeup andTable 3 Distribution of obese subjects according to obesity d
Obesity (%) Total (n = 44) T
Baseline Week 12 Δ B
I degree (BMI 30–35 Kg/m2) 23.81 47.62 + 23.81 4
II degree (BMI 35–40 Kg/m2) 33.33 23.81 - 9.52 3
III degree (BMI >40 Kg/m2) 42.86 28.57 - 14.29 2
1All values are in percentage. BMI: Body Mass Index.its interaction with dietary intake, with the aim to iden-
tify vulnerable populations/individuals that will benefit
from a variety of more personalized and mechanistic-
based dietary recommendations [36].
To the best of our knowledge, this is the first study to
evaluate the impact of C677T MTHFR genetic variant on
hysocaloric balanced nutritional intervention response in
italian obese women affected by MS. This new approach,
based on genetic and body composition evaluations, de-
fines the requirements to be assessed as guidelines to
identifying a really effective diet and could improve long
term weight management.
Because of the association of C677T MTHFR poly-
morphism with cardiovascular disease risk, osteoporosis
and sarcopenia [10,37,38], we considered the T(+) car-
riers as at risk subjects.
Our findings suggest that C677T MTHFR polymorph-
ism may play a significant role in body and metabolic fac-
tors changes, induced by HBD. In particular, all subject
responded to HBD in term of weight loss, independently
by genotype. The prevalence of MS parameters decreased
by 84% for blood pressure, by 79.5% for HDL-C, by 82%
for fasting glucose, and by 77% for triglycerides.
At baseline, T(−) carrier showed a higher level of fasting
glucose and a lower triglycerides level than T(+) carrier
(p ≤ 0.05). During the observation period, the significant
differences among the MS components occurred. Accord-
ing to the fact that, monounsaturated, and n-3 fatty acids
present in the diet help to reduce BP levels, and risk ofegree at baseline and after HBD nutritional intervention1
(−) carrier (n = 20) T (+) carrier (n = 24)
aseline Week 12 Δ Baseline Week 12 Δ
4.44 66.67 + 22.23 8.33 33.33 + 25
3.33 22.22 - 11.11 33.33 25 - 8.33
2.23 11.11 - 11.12 58.34 41.67 −16.7
Table 4 Anthropometric and body composition parameters at baseline and after HBD nutritional intervention
according to genotypes1
Parameters Baseline Week 12
Total (n = 44) T (−) (n = 20) T (+) (n = 24) Total (n = 44) T (−) (n = 20) T (+) (n = 24)
Weight (Kg) 97.79 ± 15.46 89.60 ± 14.43 103.93 ± 13.69d 88.17 ± 16.01a 80.51 ± 15.00b 93.92 ± 14.78c
BMI (Kg/m2) 40.72 ± 5.89 38.58 ± 7.23 42.32 ± 4.31 36.69 ± 6.05a 34.68 ± 7.38 38.20 ± 4.61c
Abdomen (cm) 124.43 ± 12.18 120.06 ± 12.76 127.71 ± 11.12 116.36 ± 12.59a 111.83 ± 12.54b 119.75 ± 12.02c
Hip (cm) 124.24 ± 10.94 119.22 ± 12.58 128.00 ± 8.17 116.55 ± 10.82 111.56 ± 12.09 120.29 ± 8.42c
Neck (cm) 41.93 ± 3.09 39.90 ± 2.88 42.74 ± 2.91 39.23 ± 2.90a 37.88 ± 2.36b 40.51 ± 2.98c
TBFat (Kg) 46.91 ± 8.88 41.03 ± 7.18 51.51 ± 7.57d 40.42 ± 9.36 35.21 ± 7.79b 45.29 ± 8.78c,e
TBLean (Kg) 47.67 ± 8.09 44.86 ± 6.96 50.17 ± 8.95 44.69 ± 7.26a 42.84 ± 6.61 46.33 ± 8.13c
PBF (%) 48.24 ± 3.52 46.50 ± 2.90 49.46 ± 3.56 45.87 ± 3.83a 43.57 ± 3.79 48.01 ± 2.78
BMD total body (g/cm2) 1.21 ± 0.12 1.15 ± 0.11 1.27 ± 0.11 1.19 ± 0.12a 1.14 ± 0.11 1.24 ± 0.11c, e
BMC total body (g) 2460.65 ± 351.30 2270.67 ± 255.15 2645.50 ± 355.62 2507.50 ± 408.15a 2270.67 ± 255.15 2750.60 ± 356.15c
RMR (Kcal/die) 1762.47 ± 299.00 1658.68 ± 257.43 1855.02 ± 330.95 1652.30 ± 268.55 1658.68 ± 257.43 1713.15 ± 300.66c
1All values are mean ± SD. BMI: Body Mass Index, TBFat: Total Body Fat; TBLean: Total Body Lean; PBF: Percentage of Total Body Fat; BMD: Bone Mineral Density;
BMC:Bone Mineral Content; RMR: Resting Metabolic Rate.
aReflects the significance of the differences between total population at baseline vs total population at week 12 determined with an independent t test (p ≤ 0.05).
bReflects the significance of the differences between T(−) carrier at baseline vs T(−) carrier at week 12 determined with an independent t test (p ≤ 0.05).
cReflects the significance of the differences between T(+) carrier at baseline vs T(+) carrier at week 12 determined with an independent t test (p ≤ 0.05).
dReflects the significance of the differences between T(−) carrier at baseline vs T(+) carrier at baseline determined with an independent t test (p ≤ 0.05).
eReflects the significance of the differences between T(−) carrier at week 12 vs T(+) carrier at week 12 determined with an independent t test (p ≤ 0.05).
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stolic and systolic BP levels was reduced (p ≤ 0.05). More-
over, T(−) carrier showed a lower SBP level (p ≤ 0.05). At
baseline T(+) carrier showed an higher levels of waist cir-
cumference, Tryglicerides, and lower fasting glucose (p ≤
0.05). The HBD was associated with reduction in waist cir-
cumference in total population (p ≤ 0.05), in T(−) and T
(+) carriers respectively (p ≤ 0.05). Moreover, significant
reduction of fasting glucose was observed in T(−) carrier,
more than T(+) carriers (p ≤ 0.05).
Several authors have estimated that a 1% decrease in
BMI across the United States population would prevent
more than 2 million new cases of diabetes over the next
20 years [40]. Moreover, recent lines of evidence support
the hypothesis regarding the heritability of body com-
position. Different genes may contribute to the expres-
sion of fat and lean mass. It has been well established
that TBLean, TBFat, and BMI are under strong genetic
control, with heritability of 0.52–0.72 [41].
Body composition analysis is a pivotal strength of our
study. Measures of body fat and lean distribution, could
help to stratify individuals according to their level ofTable 5 Comparison of body composition relative changes ac
Δ% Total (n = 44) (min; max) T (−) ca
Δ% weight −10.09 ± 3.57 [−19.52; −5.77] −10.42 ±
Δ% TBFat −13.52 ± 5.84 [−25.63; −3.17] −14.70 ±
Δ% TBLean −6.06 ± 4.22 [−12.84; +2.66] −4.46 ±
1All values are mean ± SD. TBFat: Total Body Fat; TBLean: Total Body Lean.
*Reflects the significance of the differences between T(−) carrier vs T(+) carrier at b
°Reflects the significance of the differences between total population vs T(−) carrierbody fat and preserved lean mass and to reveal the real
impact of a nutritional intervention [13].
In a recent study, [42] we have observed changes in
terms of body composition in an Italian Caucasian obese
population after 12 weeks of Italian Mediterranean Diet
(IMD) based on C677T MTHFR gene polymorphism.
Before the nutritional intervention, we observed differ-
ences in body composition between MTHFR genotypes
groups, indeed T(+) carriers were fatter than T(−)
carriers.
Interestingly, the highest number of responders to
IMD nutritional intervention with the lower TBLean
(Kg) loss were T(−) carriers. T(+) carriers lost more lean
mass, particularly at trunk level, and less fat mass, par-
ticularly at android level, than T(−) carriers.
The herein shown results demonstrate that 12 weeks
HBD nutritional intervention is a valid dietary approach
for loosing weight and particularly TBFat, in obese
women. However, an inter-individual variability, a well-
known phenomenon in nutrition research and practice,
was highlighted. The mechanisms responsible for the
inter-individual differences in dietary response are verycording to genotype1
rrier (n = 20) (min; max) T (+) carrier (n = 24) (min; max)
3.19 [15.54; −7.16] −10.10 ± 3.95 [− 19.52; −5.77]
5.34 [−25.63; −8.53] −12.45 ± 4.38* [−24.56; −3.17]
2.90° [−8.16; 0.44] −7.51 ± 3.17* [−12.84; 2.66]
aseline and at week 12 determined with an independent t test (p ≤ 0.05).
at baseline and at week 12 determined with an independent t test (p ≤ 0.05).
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diet interaction describes the modulation of the effect of
a dietary component on a specific phenotype, such as
obesity, by a genetic variant. A role of genetic factors
contributing to those differences in response to nutrients
has been proposed for several decades and successfully
demonstrated for rare inborn metabolism errors [43].
However, it is unknown whether low compliance to
dietary instructions, that plays an important role in body
composition, may account for the differences in the re-
sponse to nutritional interventions. It is important to note
that at the beginning of dietary plan, subjects experienced
the most dramatic weight loss, because they were very
compliant to the administered diet. Thus, in our study the
HBD was prolonged only for 12 weeks, in order to reveal
the true impact of given genetic polymorphisms or their
combination on weight loss and body composition
changes after a nutritional intervention.
At baseline, we observed differences in body compos-
ition, and metabolic parameters between MTHFR geno-
types groups. T(+) carriers were fatter than T(−) carriers,
with higer body weight and TBFat (p ≤ 0.05).
Moreover, in the 81% of the total population a loss of
Total Body Lean was observed (p ≤ 0.05).
A significative loss (p ≤ 0.05) of Total Body Lean was ob-
served in the 47% of T(−) carriers and in the 53% of T(+)
carriers.
In particular, after the HBD the presence of C677T poly-
morphism in the MTHFR gene is associated with a higher
decrease of lean mass and lower reduction of fat mass.
Interestingly, according to Δ% , the highest number of re-
sponders to HBD with the lower TBLean (Kg) loss were T
(−) carriers. As proposed by Lambrinoudaki et al. [44], the
genetic variants may lead to tissutal dysfunction, thus
causing metabolic disturbances and related body compos-
ition modification.
Reduction in lean body mass per se is an important risk
factor for sarcopenia, a serious health problem that has not
yet received sufficient attention. Sarcopenia is a syndrome
characterised by progressive and generalised loss of skeletal
muscle mass and strength with a risk of adverse outcomes,
including, but not limited, to impaired protein turnover,
mobility loss, osteoporosis, dyslipidemia, insulin resistance,
overall frailty, and increased mortality [45]. In the past dec-
ade, a number of candidate genes for obesity and osteopor-
osis have been identified [46,47], but the genetic basis of
sarcopenia is still largely unknown. Sarcopenia is usally re-
ferred to the age-related decrease in muscle quantity, qual-
ity, and function. In elderly individuals, changes in body
composition result in the prevalence of overweight and
obesity combined with a loss of muscle mass and strength;
this has recently been defined as sarcopenic obesity [48].
The combination of sarcopenia and obesity is an im-
portant public health problem that induces fragility inthe elderly, and it is associated with functional limita-
tions and increased mortality [49-52]. In order to avoid
the risk of sarcopenic obesity in the eldery, and to pre-
vent in the young population, the diagnosis of obesity re-
quires the utilization of various methods, including body
composition evaluation and a genetic approach.
In Italian males and females the relation with body
composition and anthropometric parameters and resting
metabolic rate was well described [53].
On the basis of these results, we investigated the ef-
fects of MTHFR polymorphism on resting metabolic
rate of obese women, making a comparison between T
(+) and T(−) carriers. At baseline, no significant differ-
ence of RMR was observed. However, the reduction of
RMR, observed in T(+) carriers more than in T(−) car-
riers (p ≤ 0.05), is proportional to the decrease on lean
mass, and weight loss. We conclude that the measure-
ment of energy expenditure normalised to metabolically
active mass should provide a tool to define hyper and
hypo-metabolic state during weight loss.
Liu et al. [10] propose the hypothesis that MTHFR
may exert its effect on lean body mass variation by regu-
lating mitochondria function and cell apoptosis, which
awaits further studies for validation.
Although biochemical studies are needed to confirm this
observation and to elucidate the molecular mechanisms
that underlie and explain the relationship between
MTHFR, TBFat and TBLean, this study represents a pilot
effort to explore the role of gene environment interaction
in the body composition evaluation.
An important limitation of this study is the relatively
small sample size. However, it was large enough to pro-
vide us adequate statistical power and the associations
have reached statistical significance in this context of
limited sample size. Therefore, it may be thought of as
valid and reproducible in larger samples.
Advances in the fields of molecular biology, biochem-
istry, and genetics enhanced the study of nutrition,
moving towards the realization of Predictive, Personal-
ized, Preventive and Participatory (P4) medicine [54].
The changes in medicine will trigger the emergence of
personalized nutrition, focuses on the integrated diag-
nosis, and treatment for the prevention of diseases. Our
data provide the basis for personalized dietary recom-
mendations based on the individual’s genetic makeup
and information from other factors such as gender, age,
body composition and RMR, in the context of negative
energy balance, like hypocaloric nutritional intervention
assigned to obese subjects.
A significant association was also found between protein
consumption per mealtime and loss of muscle mass [55].
For this reason, protein intake should be considered when
evaluating the multi-factorial loss of physical function in
women [56].
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lored dietary approach, particularly for T(+) carrier women,
who experienced the most dramatic loss of TBLean, assur-
ing an adequate selection of protein and omega-3 fatty
acids-rich foods to preserve muscle mass and prevent sar-
copenia. Moreover, in order to decrease hypertriglyc-
eridemia in T(+) carrier women, we suggest to increase the
omega-3 assumption (2–4 g/day).
In conclusion, our data provide evidence of interaction
between C677T MTHFR gene polymorphism and the
metabolic response to diet. This pilot study highlighted
the importance of develop personalized dietary guide-
lines to reduce MS risk among women with different
genetic background. As health care budgets become
more restricted in all countries with the passage of time,
and given the great expense involved in treating serious
complications of obesity and MS, a large-scale compre-
hensive interventions, according to the vision of social
medicine, for the prevention and control of these path-
ologies should be regarded as of public health priority.
The efficacy of genetic tests to assess in advance the
effectiveness of a dietary treatment is an undoubted
advantage for the diet therapy approach to prevent com-
plications, and reduce the social costs of a possible drug
therapy [57].
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